LGALS3 and hydrops fetalis: Consequently, Gal-3 serves as a powerful biomarker for identifying high-risk AMI patients who warrant intensified monitoring and therapeutic strategies to mitigate the risk of HF development and death (Sygitowicz et al., 2021; Idzikowska et al., 2022; Hao et al., 2024).